Foley Hoag Partner Colin Zick will join a panel discussion on “AI & Technology: Navigating Innovation, Technological Advancements and Evolving Regulations” during the 2nd Annual Bioprocessing Venture, Innovation & Partnering Conference, an event that brings together leading investors, innovators, manufacturers, and suppliers who are driving the future of bioprocessing.
The life sciences industry is transforming with advancements in artificial intelligence. The panel will explore AI innovation, regulatory frameworks and technological advancements in bioprocessing and drug development. The discussion will cover AI's role in data management, process optimization, quality control and operational efficiency, as well as regulatory challenges and opportunities. It will also examine the implications of the
Loper Bright decision, which may allow courts to overturn FDA regulations, and the US-EU collaborative efforts to evaluate AI technologies.
Additonal panelists include:
- Sherrine Eid, Global Head, Real World Evidence & Epidemiology, SAS Institute, Inc.
- Sarah Glaven, Principal Assistant Director, Biotechnology and Biomanufacturing, White House Office of Science and Technology Policy
- Nagisa Sakurai, PhD, MBA, Senior Investment Manager, Astellas Pharma
- Cenk Ündey, VP, Global Head of Pharmaceutical Technical Development Data and Digital, Roche
- Mike Walker, Executive Director - Life Sciences Supply Chain, Microsoft
